The approval is based on findings from the CIRCUIT trial published in JAMA in October 2025.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Abbott’s preliminary injunction victory means Sinocare is banned from selling its iCan i3 continuous glucose monitor (CGM) ...

Sedentary behaviour is associated with an increased risk of cardiovascular disease and all-cause mortality in people with ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the ...

Abbott (ABT) trades at $100.69 with a 24/7 Wall St. price target of $125.10 (24.24% upside) on a buy recommendation with 90% confidence. FreeStyle Libre CGM sales hit $2B in Q4 2025 with 15% year-over ...

The next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a phased roll out ...

“CGM is a powerful tool to characterize how diabetes drugs work in practice, and this work supports further research into the value of CGM, in conjunction with [A1c], as a guide to management ...

A device that combines an insulin patch pump with a continuous glucose monitor (CGM) in the same unit was shown to function in a small, early proof-of-concept study in people with type 1 diabetes (T1D ...

Chipmakers need comprehensive hardware monitoring, with monitors (Agents) and sensors distributed throughout their devices, to manage the growing complexity and scale of modern SoCs. As designs now ...